Skip to content

Clinical trials

Phase 3 Alzheimer Disease trials in Japan

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Alzheimer Disease Phase: Phase 3 Country / region: Japan Clear all

52 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20072
20084
20096
20101
20122
20132
20142
20152
20165
20172
20182
20191
20203
20213
20222
20231
20242
20258
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated21
Completed15
Recruiting9
Active, not recruiting7

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company14
Hoffmann-La Roche10
Pfizer6
Biogen4
Bristol-Myers Squibb4
AstraZeneca2
Eisai Co., Ltd.2
Novartis Pharmaceuticals2
Eidos Therapeutics, a BridgeBio company1
Eisai Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Alzheimer Disease52
Dementia11
Cognitive Dysfunction10
Plaque, Amyloid4
Amyloid Neuropathies, Familial3
Amyloidosis3
Brain Diseases3
Central Nervous System Diseases3
Mental Disorders3
Nervous System Diseases3

Trials

Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.